Company Profile
Day One Biopharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Day One Biopharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Day One Biopharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Day One Biopharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Day One Biopharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
DAWN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Day One still has OJEMDA at the center of the story, but the Mersana acquisition and the Emi-Le program are starting to widen the picture. That makes the company feel less like a single-product launch and more like an oncology platform trying to grow its options.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
Source: Day One Biopharmaceuticals
- 03
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
Source: Day One Biopharmaceuticals
- 04
- 05
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: Day One Biopharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.